A Phase 2a Study to Evaluate Viral Kinetics and Safety of Telaprevir in Participants With Genotype 2 or 3 Hepatitis C Infection

NCT00561015 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

52

Enrollment

INDUSTRY

Sponsor class

Conditions

Hepatitis C, Chronic

Interventions

DRUG: Telaprevir
DRUG: Peg-IFN-alfa-2a + Ribavirin (Standard Treatment)
DRUG: Placebo

Sponsor

Tibotec BVBA